Jagiellonian University Medical College, 1st Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Krakow, Poland.
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
J Hypertens. 2024 Dec 1;42(12):2065-2074. doi: 10.1097/HJH.0000000000003752. Epub 2024 Sep 19.
We aimed to determine the influence of coronavirus disease 2019 (COVID-19) pandemic on blood pressure (BP) control assessed by ambulatory blood pressure monitoring (ABPM).
Office BP and ABPM data from two visits conducted within a 9-15 months interval were collected from patients treated for hypertension. In the prepandemic group, both visits took place before, while in the pandemic group, Visit-1 was done before and Visit-2 during the pandemic period.
Of 1811 collected patients 191 were excluded because they did not meet the required ABPM time frames. Thus, the study comprised 704 patients from the pandemic and 916 from the prepandemic group. Groups did not differ in sex, age, duration of hypertension, frequency of first line antihypertensive drug use and mean 24 h BP on Visit-1. The prevalence of sustained uncontrolled hypertension was similar in both groups. On Visit-2 mean 24 h BP, daytime and nighttime systolic BP and diastolic BP were higher in the pandemic compared to the prepandemic group ( P < 0.034). The prevalence of sustained uncontrolled hypertension on Visit-2 was higher in the pandemic than in the prepandemic group [0.29 (95% confidence interval (95% CI): 0.26-0.33) vs. 0.25 (95% CI: 0.22-0.28), P < 0.037]. In multivariable adjusted analyses a significant difference in BP visit-to-visit change was observed, with a more profound decline in BP between visits in the prepandemic group.
This study using ABPM indicates a negative impact of the COVID-19 pandemic on BP control. It emphasizes the need of developing strategies to maintain BP control during a pandemic such as the one induced by COVID-19.
我们旨在通过动态血压监测(ABPM)评估新冠肺炎(COVID-19)大流行对血压(BP)控制的影响。
收集了接受高血压治疗的患者在 9-15 个月内两次就诊的诊室血压和 ABPM 数据。在大流行前组中,两次就诊均在大流行前进行,而在大流行组中,就诊 1 在大流行前进行,就诊 2 在大流行期间进行。
共收集了 1811 例患者,其中 191 例因未达到 ABPM 时间要求而被排除在外。因此,该研究包括大流行组的 704 例患者和大流行前组的 916 例患者。两组在性别、年龄、高血压持续时间、一线降压药物使用频率以及就诊 1 时的 24 小时平均血压方面无差异。两组的持续性未控制高血压患病率相似。就诊 2 时,大流行组的 24 小时平均血压、白天和夜间收缩压及舒张压均高于大流行前组(P 值均<0.034)。大流行组的持续性未控制高血压患病率高于大流行前组[0.29(95%置信区间(95%CI):0.26-0.33)比 0.25(95%CI:0.22-0.28),P 值均<0.037]。多变量调整分析显示,BP 就诊间变化存在显著差异,大流行前组就诊间血压下降更明显。
本研究采用 ABPM 表明 COVID-19 大流行对 BP 控制产生负面影响。它强调需要制定策略来维持大流行期间的 BP 控制,如 COVID-19 引起的大流行。